Spyre Therapeutics said it earned Great Place to Work certification for 2026, underscoring its push to position itself as an employer of choice as it expands. T

Spyre Therapeutics said it earned Great Place to Work certification for 2026, underscoring its push to position itself as an employer of choice as it expands. The biotech has also maintained visibility with investors, including meetings at Leerink’s therapeutics forum.